Asian press release distribution

Press Releases for Monday, March 6, 2023

Linkedin Influencer Rachel Mitchell Joins Plato's Board 23:30 HKT/SGT

Palladium One and MetalCorp Enter into Definitive Agreement for a Business Combination 19:30 HKT/SGT

Palladium One and MetalCorp Enter into Definitive Agreement for a Business Combination 19:30 HKT/SGT

World Premiere of the All-New Crown Series 18:46 HKT/SGT

世界听力日「乜嘢话」长者听力慈惠计划启动礼 16:59 HKT/SGT

Axiata Joins Global Telcos to Deploy GSMA Open Gateway at MWC Barcelona 2023 16:00 HKT/SGT

日立パワーソリューションズが太陽光発電協調型風力発電システムを初納入 16:00 HKT/SGT

Sri Trang Agro-Industry Founder Somwang Sincharoenkul Passes on at 97 16:00 HKT/SGT

Two Indonesian Elementary Schools Built with Support of Mitsubishi Motors Hold Opening Ceremonies 15:55 HKT/SGT

医思健康香港自建旗舰宠物医院正式开幕 15:52 HKT/SGT

醫思健康香港自建旗艦寵物醫院正式開幕 15:51 HKT/SGT

EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong 15:50 HKT/SGT

KDDI・三菱重工・NECネッツエスアイ、データセンター内のサーバーを液体冷却、冷却電力の94%減を達成 15:45 HKT/SGT

MC Signs Integrated Railway Systems and Trackwork Contract for North-South Commuter Railway Extension Project in the Philippines 14:16 HKT/SGT

Society Pass Inc. (Nasdaq: SOPA)'s NusaTrip Continues Expansion in Southeast Asia (SEA), Extending Services to Vietnam 14:00 HKT/SGT

三菱商事、フィリピン共和国南北通勤鉄道延伸向け鉄道システム一式契約締結について発表 11:00 HKT/SGT

Honda、米国で燃料電池（FC）定置電源の実証運用を開始 10:54 HKT/SGT

エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請（sBLA）が米国FDAに受理され、優先審査に指定 10:00 HKT/SGT

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease 09:58 HKT/SGT

Honda's Zero Emission Stationary Fuel Cell Provides Back Up Power to a Data Center 09:43 HKT/SGT

ACN Search:

CITIC Telecom CPC Becomes New VMware Cloud Service Provider Pinnacle Tier Partner in the Broadcom Advantage Partner Program


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575